PD Prevention vs Treatment Scorecard

PD Prevention vs Treatment Scorecard

Introduction

This page provides a systematic comparison of prevention versus treatment approaches for Parkinson's Disease (PD). While current therapies primarily address symptoms, there is growing emphasis on disease-modifying strategies and prevention. This scorecard evaluates each therapeutic approach on two dimensions: Prevention Potential (ability to delay or prevent onset in at-risk individuals) and Treatment Potential (ability to slow, halt, or reverse progression in diagnosed patients).

Overview

This page provides a systematic comparison of prevention versus treatment approaches for Parkinson's Disease (PD). While current therapies primarily address symptoms, there is growing emphasis on disease-modifying strategies and prevention. This scorecard evaluates each therapeutic approach on two dimensions: Prevention Potential (ability to delay or prevent onset in at-risk individuals) and Treatment Potential (ability to slow, halt, or reverse progression in diagnosed patients).

The analysis synthesizes evidence from prevention trials, risk factor studies, and disease-modifying therapy research to provide actionable recommendations for clinicians, researchers, and patients. [@ascherio]

Prevention vs Treatment Scorecard

The following table scores each major PD therapeutic approach on both prevention and treatment potential (0-10 scale):

PD Prevention vs Treatment Scorecard

Introduction

This page provides a systematic comparison of prevention versus treatment approaches for Parkinson's Disease (PD). While current therapies primarily address symptoms, there is growing emphasis on disease-modifying strategies and prevention. This scorecard evaluates each therapeutic approach on two dimensions: Prevention Potential (ability to delay or prevent onset in at-risk individuals) and Treatment Potential (ability to slow, halt, or reverse progression in diagnosed patients).

Overview

This page provides a systematic comparison of prevention versus treatment approaches for Parkinson's Disease (PD). While current therapies primarily address symptoms, there is growing emphasis on disease-modifying strategies and prevention. This scorecard evaluates each therapeutic approach on two dimensions: Prevention Potential (ability to delay or prevent onset in at-risk individuals) and Treatment Potential (ability to slow, halt, or reverse progression in diagnosed patients).

The analysis synthesizes evidence from prevention trials, risk factor studies, and disease-modifying therapy research to provide actionable recommendations for clinicians, researchers, and patients. [@ascherio]

Prevention vs Treatment Scorecard

The following table scores each major PD therapeutic approach on both prevention and treatment potential (0-10 scale):

| Approach | Prevention Potential | Treatment Potential | Evidence Level | Key Considerations |
|----------|:-------------------:|:------------------:|----------------|-------------------|
| Levodopa/Carbidopa/Entacapone | 2 | 10 | High | Gold standard for motor symptoms; no disease-modifying evidence |
| MAO-B Inhibitors | 3 | 9 | High | Possible neuroprotective effects; widely used early |
| Dopamine Agonists | 2 | 8 | High | Motor symptom control; no prevention data |
| COMT Inhibitors | 2 | 8 | High | Adjunctive therapy; levodopa optimization |
| Deep Brain Stimulation | 0 | 9 | High | Surgical intervention for advanced disease |
| Exercise & Lifestyle | 8 | 7 | High | Strongest prevention evidence; improves symptoms |
| GLP-1 Agonists | 5 | 6 | Moderate | Disease-modifying signals in Phase 2 |
| Gene Therapy (AAV-AADC) | 1 | 5 | Moderate | Targets motor symptoms; no prevention role |
| Cell Therapy (DANSR) | 1 | 5 | Moderate | Dopamine replacement; no prevention data |
| Alpha-Syn Immunotherapy | 6 | 7 | Moderate | Active trials in prodromal/early PD |
| Mitophagy Activators | 5 | 6 | Low | Preclinical promise; early clinical |
| Iron Chelators | 4 | 4 | Low | Targeting iron accumulation; uncertain efficacy |
| GDNF/Neurotrophic Factors | 3 | 5 | Moderate | Regenerative potential; delivery challenges |
| [Microbiome](/entities/microbiome) Modulation | 6 | 5 | Low | Emerging field; [gut-brain axis](/entities/gut-brain-axis) research |
| Antioxidants (CoQ10, Vitamin E) | 4 | 3 | Low | Mixed trial results; theoretical benefit |

Prevention Trials in Parkinson's Disease

Completed Prevention Trials

DATATOP (1987-1993)

• Design: 800 newly diagnosed, untreated PD patients randomized to deprenyl (MAO-B inhibitor), tocopherol (vitamin E), both, or placebo
• Primary Outcome: Time to require levodopa therapy
• Key Findings:
• Deprenyl significantly delayed disability requiring levodopa (hazard ratio 0.45, p<0.001)
• Vitamin E showed no significant effect
• Symptomatic effect of deprenyl confounded interpretation
• Limitations: Unable to distinguish neuroprotection from symptomatic benefit
• References: [@cui2026]

ADAGIO (2009-2014)

• Design: 1,176 newly diagnosed PD patients randomized to rasagiline 1mg/day, 2mg/day, or placebo
• Primary Endpoint: Change in Unified Parkinson's Disease Rating Scale (UPDRS) in placebo-controlled, dose-response design
• Key Findings:
• 1mg dose showed disease-modifying effect (delayed progression)
• 2mg dose did not meet primary endpoint (possible confounding)
• Controversy: Interpretation remains debated in field
• References: [@ahuja2026]

TEMPO (2004-2006)

• Design: 404 early PD patients randomized to rasagiline 1mg, 2mg, or placebo
• Primary Endpoint: Change in UPDRS score at 12 months
• Key Findings:
• Both doses showed symptomatic benefit
• Delayed need for additional therapy
• References: [@pham2026]

NET-PD (2007-2015)

• Design: 1,741 early PD patients randomized to creatine 10g/day vs placebo
• Primary Outcome: Change in UPDRS score at 5 years
• Key Findings:
• No significant difference in progression (hazard ratio 0.93, p=0.21)
• Slow recruitment limited power
• References: [@lui2026]

Ongoing Prevention Trials

AHEAD 3-45 (Active)

PPMI (Parkinson's Progression Markers Initiative)

• Key Findings:
• Hyposmia, RBD, and smell testing identify prodromal PD
• DAT imaging identifies individuals before motor symptoms
• Genetic risk scores (LRRK2, GBA) enrich for at-risk populations

Risk Factor Analysis

Genetic Risk Factors

| Risk Factor | Relative Risk | Prevention Implications |
|-------------|---------------|-------------------------|
| LRRK2 G2019S | 6-8x | Penetrance variable; modifier genes may modulate |
| GBA N370S | 4-5x | Lysosomal dysfunction targetable |
| SNCA Multiplication | 2-3x | [Alpha-synuclein](/proteins/alpha-synuclein) expression modifiable |
| PARK2 (Parkin) | Recessive | Early-onset; different phenotype |
| PINK1 | Recessive | Mitophagy enhancement possible |
| [APOE](/proteins/apoe) ε4 | 2-3x | Lipid metabolism, inflammation |

Environmental Risk Factors

| Factor | Effect | Evidence | Prevention Potential |
|--------|--------|----------|----------------------|
| Pesticide Exposure | 1.5-2x risk | Strong | Occupational protection |
| Rural Living | 1.3x risk | Moderate | Water source protection |
| Head Trauma | 1.5x risk | Moderate | Safety equipment |
| Milk Consumption | 1.3x risk | Weak | Uncertain mechanism |
| Low Vitamin D | 1.4x risk | Moderate | Supplementation trials |

Protective Factors

| Factor | Hazard Ratio | Evidence | Translation |
|--------|-------------|----------|-------------|
| Regular Exercise | 0.6-0.7 | Strong | Immediate implementation |
| Caffeine | 0.7 | Moderate | Dose optimization |
| Smoking | 0.6 (paradoxical) | Confounded | Not recommended |
| NSAID Use | 0.7 | Moderate | Anti-inflammatory |
| Physical Activity | 0.5 | Strong | Dose-response |

Mermaid.js: Clinical Decision Framework

Therapeutic Approaches: Prevention vs Treatment Comparison

Symptomatic Therapies (Primarily Treatment)

These approaches primarily address motor symptoms without clear disease-modifying effects:

• Gold standard for motor symptoms
• Long-term use associated with dyskinesias
• No evidence for disease modification

• May provide mild neuroprotection via MAO-B inhibition
• ADAGIO suggested possible disease modification
• Widely used in early PD

• Pramipexole, ropinirole, rotigotine
• Motor complications less than levodopa
• Impulse control disorders a concern

Disease-Modifying Candidates (Both Prevention & Treatment)

• Phase 2 trial showed motor benefit persisting after washout
• Anti-inflammatory and neurotrophic effects
• REWIND trial ongoing for Parkinson's
• References: [@peng2025]

• Active and passive immunization approaches in trials
• Targets: PD-01 (AFFiRiS), Cinq-U3 (Prothelia), BIIB054 (Biogen)
• PRIME trial showed safety in early PD
• Prevention trials in prodromal populations planned

Lifestyle & Preventive Approaches

• Strongest evidence for neuroprotection
• UPDRS improvements of 2-5 points
• Multiple mechanisms: neurotrophic factors, anti-inflammatory, stress resilience

• Ketogenic diet may support mitochondrial function
• Mediterranean diet anti-inflammatory
• Caloric restriction activates [autophagy](/entities/autophagy)

• REM sleep behavior disorder is prodromal marker
• Sleep quality affects glymphatic clearance
• Treatment of sleep disorders may reduce risk

Emerging & Investigational

• AAV-AADC for motor symptoms (already approved in some regions)
• Gene silencing approaches (ASOs) for GBA, LRRK2
• No prevention applications currently

• Dopamine neuron transplantation (DANSR)
• iPSC-derived [neurons](/entities/neurons) in trials
• No prevention applications

• Fecal microbiota transplantation trials
• Probiotic interventions
• Diet modification effects on gut-brain axis

Recommendations

For At-Risk Individuals (Prevention Focus)

For Newly Diagnosed Patients (Early Intervention)

For Established PD (Treatment + Prevention)

Cross-Links to Related Pages

• [PD Therapeutic Scorecard](/mechanisms/pd-therapeutic-scorecard) - Detailed scoring of all approaches
• [PD Knowledge Gaps](/mechanisms/pd-knowledge-gaps-ranked) - Research priorities
• [PD Combination Therapy Matrix](/mechanisms/pd-combination-therapy-matrix) - Synergistic approaches
• [Alpha-Synuclein Pathway](/mechanisms/synuclein-pathway-parkinsons) - Core pathology
• [Mitochondrial Dysfunction Pathway](/mechanisms/mitochondrial-dysfunction-pathway) - Energy metabolism
• [Dopaminergic Vulnerability](/mechanisms/dopaminergic-vulnerability) - Selective neuronal vulnerability
• [GBA Lysosomal Pathway](/mechanisms/gba-lysosomal-pathway-parkinsons) - Genetic risk
• [LRRK2 Pathway](/mechanisms/lrrk2-pathway-parkinsons) - Kinase dysfunction

See Also

• [Mechanisms/Pd-Prevention-Vs-Treatment](/mechanisms/pd-prevention-vs-treatment) — This page

Background

The study of Pd Prevention Vs Treatment Scorecard has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
• [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
• [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data

Recent Research Updates (2024-2026)

Recent publications highlighting key advances in this mechanism:

• Temporal Sequence of Cognitive Function and ADLs and Mediation Effect of Apathy in Parkinson's Disea... [@cui2026]
• Benztropine. [@ahuja2026]
• Rapid Eye Movement Sleep Behavior Disorder. [@pham2026]
• Alzheimer Disease. [@lui2026]
• Calcium bridges built by mitochondria-associated endoplasmic reticulum membranes: potential targets ... [@peng2025]

References

Pathway Diagram

The following diagram shows the key molecular relationships involving PD Prevention vs Treatment Scorecard discovered through SciDEX knowledge graph analysis: